Century Therapeutics, Inc. (IPSC) Tops Q2 EPS by 7c

Century Therapeutics, Inc. (NASDAQ: IPSC) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $800 thousand versus the consensus estimate of $430 thousand.

For earnings history and earnings-related data on Century Therapeutics, Inc. (IPSC) click here.

You May Also Be Interested In

• Gulfport Energy and Mobility Global to join S&P SmallCap 600
• Tractor Supply and Starlink team up to expand rural broadband via 4-H
• FDA approves AbbVie's Skyrizi for children with psoriatic disease